C0001186||azaacridine derivatives
C0034802||EGFR
C0282625||Src kinase
C3537035||inhibitors
C0087111||treatment
C1514559||Overexpression
C0034802||EGFR
C0012634||disease
C0278252||poor prognosis
C0007097||cancers
C0282625||Src
C0034802||EGFR
C0596290||proliferation
C0007620||survival
C2699153||invasion
C4255448||metastasis
C0013227||drugs
C0034802||EGFR
C0282625||Src
C0007097||cancers
C3494274||molecular docking
C2603343||studies
C0001186||azaacridine derivatives
C0034802||EGFR
C0282625||Src
C3537035||inhibitors
C0001186||azaacridines
C0600432||K562
C4277577||A549 cells
C1254351||compound 13b
C0600432||K562
C4277577||A549 cells
C0034802||EGFR
C0282625||Src
C1254351||compound 13b
C1171362||expression
C0034802||EGFR
C0034802||p-EGFR
C0282625||Src
C0282625||p-Src
C1254351||13b
C1269955||invasion of tumor cells
C0334227||cancer cells
C0162638||apoptosis
C2603343||study
C0001186||azaacridine
C3537035||multi-target kinase inhibitors
C0920425||cancer therapy